Curasight has entered a new clinical phase with both arms of its uPAR-based theranostic platform now in clinical development, following the successful first patient dosing in the Phase I uTREAT® trial in glioblastoma and continued progress in the Phase II uTRACE® prostate cancer study under the partnership with Curium. With diagnostic proof-of-concept already established across multiple indications, the transition of uTREAT® into human trials materially expands the company’s addressable market and shifts investor focus toward the therapeutic upside embedded in the platform.

At current valuation levels, we believe the market is increasingly pricing in optionality around uTREAT®, despite the program remaining at an early clinical stage. The initiation of first-in-human dosing increases both upside potential and execution risk, as the upcoming preliminary data read-out will be the first indication of whether preclinical efficacy can translate into a clinically viable therapeutic signal.

Looking ahead, the initial uTREAT® data read-out, expected before year-end 2025, represents a key inflection point for Curasight’s theranostic ambitions. Supportive safety and feasibility data could validate the combined uTRACE®/uTREAT® approach and enable progression toward a broader multi-indication basket trial in 2026. As a result, near-term valuation sensitivity has risen, with the market now implicitly pricing in some probability of success for the basket trial and hence raising near-term clinical risk relating to the data. The potential of Curasight’s theranostic approach based on uPAR remains significant, and a positive read-out can open the door for a larger partnership agreement in 2026.

Disclaimer: HC Andersen Capital receives payment for a digitalIR/Corporate visibility subscription agreement. / Philip Coombes 12:35 22/12-2025